Drug Profile
Lancovutide
Alternative Names: 2622U90; Duramycin; Moli 1901; PA 48009Latest Information Update: 12 Aug 2022
Price :
$50
*
At a glance
- Originator Lantibio
- Developer AOP Orphan Pharmaceuticals AG; Lantibio
- Class Expectorants; Peptides
- Mechanism of Action Chloride channel agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Dry eyes
- Discontinued Cystic fibrosis
Most Recent Events
- 12 Aug 2022 Discontinued - Phase-II for Cystic fibrosis in Austria (Inhalation) (EudraCT2005-005594-29)
- 12 Aug 2022 Discontinued - Phase-III for Cystic fibrosis in Czech Republic (Inhalation) (EudraCT2005-005594-29)
- 12 Aug 2022 Discontinued - Phase-III for Cystic fibrosis in Hungary (Inhalation) (EudraCT2005-005594-29)